0001768245-20-000003.txt : 20201230 0001768245-20-000003.hdr.sgml : 20201230 20201230171300 ACCESSION NUMBER: 0001768245-20-000003 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20201230 DATE AS OF CHANGE: 20201230 EFFECTIVENESS DATE: 20201230 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Viewpoint Molecular Targeting, Inc. CENTRAL INDEX KEY: 0001768245 IRS NUMBER: 263526327 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-382294 FILM NUMBER: 201426606 BUSINESS ADDRESS: STREET 1: 2500 CROSSPARK ROAD E-116 CITY: CORALVILLE STATE: IA ZIP: 52241 BUSINESS PHONE: 8653561861 MAIL ADDRESS: STREET 1: 2500 CROSSPARK ROAD E-116 CITY: CORALVILLE STATE: IA ZIP: 52241 D/A 1 primary_doc.xml X0708 D/A LIVE 0001768245 Viewpoint Molecular Targeting, Inc. 2500 CROSSPARK ROAD E-116 CORALVILLE IA IOWA 52241 8653561861 DELAWARE Viewpoint Molecular Targeting, LLC None Corporation true Frances Johnson 2500 Crosspark Road E-116 Coralville IA IOWA 52241 Executive Officer Director Michael Schultz 2500 Crosspark Road E-116 Coralville IA IOWA 52241 Executive Officer Director Heyward Coleman 2500 Crosspark Road E-116 Coralville IA IOWA 52241 Executive Officer Director Curtis Nelson 2500 Crosspark Road E-116 Coralville IA IOWA 52241 Director Cameron Gray 1221 Shafter Street San Mateo CA CALIFORNIA 94402 Director Biotechnology Decline to Disclose 06b true 0001768245-20-000002 2020-11-20 false true false 25000 National Securities Corporation 7569 None None 5000 T-Rex Avenue Suite 300 Boca Raton FL FLORIDA 33431 CA CALIFORNIA DC DISTRICT OF COLUMBIA FL FLORIDA IL ILLINOIS IA IOWA MD MARYLAND NE NEBRASKA SC SOUTH CAROLINA TX TEXAS false 15847498 12038744 3808754 Total offering amount is subject to increase by the issuer. Total offering amount and total amount sold include conversion of outstanding debt in the aggregate amount of $847,498. false 28 868231 0 Cash sales compensation of $818,230.92 and reimbursed expenses of $50,000. Additionally, warrants to purchase 869,841 shares of common stock of the issuer at the per share offering price were issued to the broker. 500000 true Compensation to executive officers in the ordinary course pursuant to their Board-approved existing employment agreements. false Viewpoint Molecular Targeting, Inc. Frances L. Johnson Frances L. Johnson CEO 2020-12-30